OliX Pharmaceuticals, Inc (KOSDAQ:226950)

South Korea flag South Korea · Delayed Price · Currency is KRW
180,000
+20,600 (12.92%)
At close: Feb 27, 2026
Market Cap3.63T +1,145.2%
Revenue (ttm)10.18B -36.9%
Net Income-43.30B
EPS-2,280.15
Shares Out20.19M
PE Ration/a
Forward PE330.38
Dividendn/a
Ex-Dividend Daten/a
Volume802,519
Average Volume400,913
Open160,900
Previous Close159,400
Day's Range160,400 - 185,500
52-Week Range34,500 - 185,500
Beta0.55
RSI71.05
Earnings DateMar 20, 2026

About OliX Pharmaceuticals

OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 226950
Full Company Profile

Financial Performance

In 2024, OliX Pharmaceuticals's revenue was 5.68 billion, a decrease of -66.73% compared to the previous year's 17.06 billion. Losses were -40.66 billion, 112.9% more than in 2023.

Financial Statements